The influence of recombinant human erythropoietin (r-HuEPO) on erythrocyte vitamins Bi, B
was investigated in regular dialysis treatment (RDT) patients during a long-term 9-month study. Twenty-six RDT patients were divided into two groups. Group A was without r-HuEPO treatment while group B was treated by subcutaneous injection of r-HuEPO. The total maintenance weekly dose of r-HuEPO was 50-100 U/kg. Group A of patients was supplemented with oral pyridoxine 5 mg/day during the period of 9 months; group B was supplemented with oral pyridoxine 5 mg/day for the first 6 months and with 20 mg/day during the following 3 months. At the end of the study, significant increase in erythrocyte vitamin B
and significant decrease in erythrocyte vitamin B6 were found. Supplementation with 20 mg/day of pyridoxine led to a significant increase in vitamin B6 and at the end of the 9 months, the values of vitamin B
were within the normal range. These results provide indirect evidence that erythrocyte vitamin B
is consumed by the hemoglobin synthesis during r-HuEPO treatment in RDT patients.
Prof. Miroslav Mydlík, MUDr, DrSc, Fourth Medical Clinic, University Hospital of Louis Pasteur, Rastislavova 43, 041 90 Košice (Slovak Republic)
Received: May 7, 1993
Accepted: August 27, 1993
Published online: October 28, 2008
Number of Print Pages : 3
American Journal of Nephrology
Vol. 13, No. 6, Year 1993 (Cover Date: 1993)
Journal Editor: Bakris G. (Chicago, Ill.)
ISSN: 0250–8095 (Print), eISSN: 1421–9670 (Online)
For additional information: http://www.karger.com/AJN
Copyright / Drug Dosage
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.